Author:
Moreira Alvaro,Loquai Carmen,Pföhler Claudia,Kähler Katharina C.,Knauss Samuel,Heppt Markus V.,Gutzmer Ralf,Dimitriou Florentia,Meier Friedegund,Mitzel-Rink Heidrun,Schuler Gerold,Terheyden Patrick,Thoms Kai-Martin,Türk Matthias,Dummer Reinhard,Zimmer Lisa,Schröder Rolf,Heinzerling Lucie
Reference60 articles.
1. A review of serious adverse effects under treatment with checkpoint inhibitors;Heinzerling;Curr Opin Oncol,2017
2. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy;Hofmann;Eur J Cancer (Oxford, England: 1990),2016
3. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy;Zimmer;Eur J Cancer (Oxford, England: 1990),2016
4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
5. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献